Loading…
Goldline Pharmaceutical (BSE 544759)₹29.74−3.69%Pharmaceuticals
In the Mar 2026 quarter (standalone), Goldline Pharmaceutical reported sales of ₹17.35 Cr and net profit of ₹2.75 Cr. For the year to Mar 2026, sales were ₹31.26 Cr and net profit ₹4.11 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Sep 2025 | Mar 2026 | |
|---|---|---|
| Sales | 13.93 | 17.35 |
| Expenses | 11.26 | 13.01 |
| Operating Profit | 2.65 | 4.32 |
| OPM % | 19.1% | 24.9% |
| Other Income | 0.00 | 0.00 |
| Interest | 0.68 | 0.66 |
| Depreciation | 0.11 | 0.11 |
| Profit before tax | 1.86 | 3.53 |
| Tax % | 26.4% | 21.7% |
| Net Profit | 1.35 | 2.75 |
| EPS (Rs) | 1.98 | 4.01 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 19.79 | 23.54 | 28.08 | 31.26 |
| Expenses | 17.33 | 19.16 | 21.89 | 24.10 |
| Operating Profit | 2.42 | 4.35 | 6.16 | 7.10 |
| OPM % | 12.2% | 18.5% | 22.0% | 22.8% |
| Other Income | −0.19 | −0.03 | −0.08 | 0.00 |
| Interest | 1.64 | 1.62 | 1.96 | 1.47 |
| Depreciation | 0.17 | 0.15 | 0.24 | 0.23 |
| Profit before tax | 0.39 | 2.54 | 3.85 | 5.38 |
| Tax % | 37.4% | 28.4% | 26.4% | 23.3% |
| Exceptional items | −0.14 | −0.04 | −0.08 | 0.00 |
| Net Profit | 0.25 | 1.80 | 2.82 | 4.11 |
| EPS (Rs) | 1.31 | 7.89 | 4.11 | 5.98 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 1.99 | 2.29 | 6.88 | 6.88 |
| Reserves | 2.07 | 3.75 | 1.54 | 5.53 |
| Borrowings | 12.62 | 12.92 | 12.83 | 10.94 |
| Other Liabilities | 2.68 | 3.91 | 4.88 | 5.47 |
| Total Liabilities | 19.36 | 22.87 | 26.13 | 28.82 |
| Fixed Assets | 2.51 | 2.96 | 2.90 | 2.72 |
| CWIP | 0.00 | 0.44 | 0.00 | 0.00 |
| Investments | 0.06 | 0.02 | 0.02 | 0.02 |
| Other Assets | 16.79 | 19.45 | 23.21 | 26.08 |
| Inventories | 5.35 | 7.46 | 6.75 | 6.19 |
| Trade receivables | 8.65 | 9.64 | 10.72 | 16.17 |
| Cash & equivalents | 0.06 | 0.80 | 1.25 | 0.60 |
| Total Assets | 19.36 | 22.87 | 26.13 | 28.82 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | 2.40 | 2.93 | 3.19 | 2.82 |
| Cash from investing activity | −1.05 | −1.12 | 0.17 | −0.07 |
| Cash from financing activity | −1.43 | −1.07 | −2.88 | −3.39 |
| Net cash flow | −0.08 | 0.73 | 0.44 | −0.66 |
| Capex | 1.12 | 1.12 | 0.22 | 0.07 |
| Free cash flow | 1.37 | 1.80 | 3.34 | 2.74 |
| CFO / OP % | 100.9% | 72.0% | 66.0% | 53.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 161 | 151 | 140 | 190 |
| Inventory days | 337 | 451 | 230 | 203 |
| Days payable | 53 | 98 | 69 | 59 |
| Cash conversion cycle | 442 | 502 | 300 | 332 |
| Working capital days | 144 | 133 | 134 | 156 |
| ROCE % | — | 23.3% | 29.2% | 30.6% |
For the Mar 2026 quarter, Goldline Pharmaceutical reported sales of ₹17.35 Cr and net profit of ₹2.75 Cr. The operating margin was 24.9%.
Goldline Pharmaceutical's sales for the year to Mar 2026 were ₹31.26 Cr.
Net profit for the year to Mar 2026 was ₹4.11 Cr. Earnings per share over the same trailing period were ₹5.98.
Goldline Pharmaceutical reported borrowings of ₹10.94 Cr at Mar 2026, against cash and equivalents of ₹0.60 Cr.
Cash from operations was ₹2.82 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹2.74 Cr.